Loading
A phase 3 trial testing Bezuclastinib in gastrointestinal stromal tumour, now recruiting.
(Peak) A Phase 3 Randomised Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumours is a phase 3 interventional study registered as NCT05208047, led by Cogent Biosciences, and recruiting on the registry. Official title: A Phase 3 Randomised, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumours. Planned enrolment is 482 participants (estimated). The study started in 2022-04-14 and primary completion was reached in 2025-09-30. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bezuclastinib, Cogent Biosciences.
Shares Bezuclastinib, Cogent Biosciences.
Shares Bezuclastinib, Gastrointestinal stromal tumour (GIST).
Shares Bezuclastinib, Gastrointestinal stromal tumour (GIST).
Shares Bezuclastinib, Cogent Biosciences, Gastrointestinal stromal tumour (GIST).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/